Recent trials show efficacy of SGLT-2 inhibitors in reducing the hospitalization for heart failure and progression of renal disease especially in diabetic patients 27,28 and sacubtril-valsartan improves outcomes of heart failure in patients with ESRD.1 This presents promising area for future studies in terms of comparing the outcomes of treatment modalities for heart failure in diabetics with kidney disease. The gene discussed is SLC5A2; the disease is heart failure.